Allianz Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-21,000
| Closed | -$791K | – | 2536 |
|
|
2021
Q1 | $791K | Buy |
21,000
+3,880
| +23% | +$96.8K | ﹤0.01% | 1735 |
|
|
2020
Q4 | $291K | Buy |
+17,120
| New | +$214K | ﹤0.01% | 1751 |
|
|
2016
Q4 | – | Sell |
-15,342
| Closed | -$805K | – | 2708 |
|
|
2016
Q3 | $805K | Sell |
15,342
-51,255
| -77% | -$2.45M | ﹤0.01% | 2269 |
|
|
2016
Q2 | $2.75M | Sell |
66,597
-1,707
| -2% | -$74.3K | ﹤0.01% | 1780 |
|
|
2016
Q1 | $2.77M | Sell |
68,304
-8,713
| -11% | -$299K | ﹤0.01% | 1659 |
|
|
2015
Q4 | $3.2M | Sell |
77,017
-1,261
| -2% | -$42.3K | ﹤0.01% | 1522 |
|
|
2015
Q3 | $1.21M | Buy |
78,278
+1,468
| +2% | +$31.5K | ﹤0.01% | 1755 |
|
|
2015
Q2 | $1.91M | Buy |
+76,810
| New | +$1.71M | ﹤0.01% | 1723 |
|
|
2014
Q3 | – | Sell |
-35,400
| Closed | -$550K | – | 2394 |
|
|
2014
Q2 | $550K | Sell |
35,400
-3,658
| -9% | -$52.5K | ﹤0.01% | 1556 |
|
|
2014
Q1 | $768K | Sell |
39,058
-20,883
| -35% | -$355K | ﹤0.01% | 1465 |
|
|
2013
Q4 | $1.01M | Buy |
+59,941
| New | +$745K | ﹤0.01% | 1399 |
|
Allianz Asset Management's FPRX Position: Q2 2021 in Review
Allianz Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 21,000 shares — an estimated $791K sold.
Allianz Asset Management first reported a position in FPRX in Q4 2013 and held it in 11 quarters. The position peaked at $3.2M in Q4 2015. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Allianz Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Allianz Asset Management sold 21,000 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $791K.
- Allianz Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 11 quarters.
- Allianz Asset Management's Five Prime Therapeutics, Inc. position peaked at $3.2M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Allianz Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.